Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis

Shubber, Zara; Calmy, Alexandra; Andrieux-Meyer, Isabelle; Vitoria, Marco; Renaud-Théry, Françoise; Shaffer, Nathan; Hargreaves, Sally; Mills, Edward J; Ford, Nathan

doi:10.1097/QAD.0b013e32835f1db0

Scientific article

Review

English

Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis

ContributorsShubber, Zara; Calmy, Alexandra

; Andrieux-Meyer, Isabelle; Vitoria, Marco; Renaud-Théry, Françoise; Shaffer, Nathan; Hargreaves, Sally; Mills, Edward J; Ford, Nathan

Published inAIDS, vol. 27, no. 9, p. 1403-1412

Publication date2013

Abstract

Since 2002, the WHO has recommended either nevirapine (NVP) or efavirenz (EFV) as part of first-line antiretroviral therapy. These two drugs are known to have differing toxicity profiles, but the risk of these toxicities overall is not well established.

Keywords

Adult
Anti-HIV Agents/administration & dosage/adverse effects
Benzoxazines/administration & dosage/adverse effects
Child
HIV Infections/drug therapy
Humans
Nevirapine/administration & dosage/adverse effects
Randomized Controlled Trials as Topic
Reverse Transcriptase Inhibitors/administration & dosage/adverse effects

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

VIH/SIDA (930)

Citation (ISO format)

SHUBBER, Zara et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. In: AIDS, 2013, vol. 27, n° 9, p. 1403–1412. doi: 10.1097/QAD.0b013e32835f1db0

Article (Published version)

Identifiers

PID : unige:33911
DOI : 10.1097/QAD.0b013e32835f1db0
PMID : 23343913

Journal ISSN0269-9370

635views

0downloads

Creation03/12/2013 15:47:00

First validation03/12/2013 15:47:00

Update time14/03/2023 20:56:05

Status update14/03/2023 20:56:04

Last indexation30/10/2024 16:08:50

Archive ouverte UNIGE

Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis

Since 2002, the WHO has recommended either nevirapine (NVP) or efavirenz (EFV) as part of first-line antiretroviral therapy. These two drugs are known to have differing toxicity profiles, but the risk of these toxicities overall is not well established.

Technical informations